Investigating human cancer etiology by DNA lesion footprinting and mutagenicity analysis

Carcinogenesis

Volumn 27, Issue 8, 2006, Pages 1526-1537

  Besaratinia, Ahmad ^a   Pfeifer, Gerd P ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; NUCLEOTIDE; TRANSFERASE;

CANCER; CARCINOGEN TESTING; CARCINOGENESIS; CARCINOGENICITY; DNA DAMAGE; DNA FINGERPRINTING; GENE SEQUENCE; GENOTOXICITY; HUMAN; IN VITRO STUDY; MUTAGEN TESTING; MUTATION; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RODENT; SHUTTLE VECTOR; SITE DIRECTED MUTAGENESIS; TRANSGENIC ANIMAL; TUMOR SUPPRESSOR GENE;

DNA DAMAGE; DNA FOOTPRINTING; DNA, NEOPLASM; HUMANS; MUTAGENICITY TESTS; NEOPLASMS;

EID: 33747874880     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi311     Document Type: Review

References (97)

1. Church,G.M. and Gilbert,W. (1984) Genomic sequencing. Proc. Natl Acad. Sci. USA, 81, 1991-1995.
2. Becker,P.B., Ruppert,S. and Schutz,G. (1987) Genomic footprinting reveals cell type-specific DNA binding of ubiquitous factors. Cell, 51, 435-443.
3. Mueller,P.R. and Wold,B. (1989) In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science, 246, 780-786.
4. Pfeifer,G.P., Steigerwald,S.D., Mueller,P.R., Wold,B. and Riggs,A.D. (1989) Genomic sequencing and methylation analysis by ligation mediated PCR. Science, 246, 810-813.
5. Saluz,H. and Jost,J.P. (1989) A simple high-resolution procedure to study DNA methylation and in vivo DNA-protein interactions on a single-copy gene level in higher eukaryotes. Proc. Natl Acad. Sci. USA, 86, 2602-2606.
6. Yandell,D.W. and Dryja,T.P. (1989) Detection of DNA sequence polymorphisms by enzymatic amplification and direct genomic sequencing. Am. J. Hum. Genet., 45, 547-555.
7. Chen,H.H., Kontaraki,J., Bonifer,C. and Riggs,A.D. (2001) Terminal transferase-dependent PCR (TDPCR) for in vivo UV photofootprinting of vertebrate cells. Sci. STKE, 2001, PL1.
8. Chen,H.H., Castanotto,D., LeBon,J., Rossi,J.J. and Riggs,A.D. (2004) In vivo detection of ribozyme cleavage products and RNA structure by use of terminal transferase-dependent PCR. Methods Mol. Biol., 252, 109-124.
9. Becker,M.M., Wang,Z., Grossmann,G. and Becherer,K.A. (1989) Genomic footprinting in mammalian cells with ultraviolet light. Proc. Natl Acad. Sci. USA, 86, 5315-5319.
10. Dai,S.M., Chen,H.H., Chang,C., Riggs,A.D. and Flanagan,S.D. (2000) Ligation-mediated PCR for quantitative in vivo footprinting. Nat. Biotechnol., 18, 1108-1111.
11. Ingram,R., Tagoh,H., Riggs,A.D. and Bonifer,C. (2005) Rapid, solid-phase based automated analysis of chromatin structure and transcription factor occupancy in living eukaryotic cells. Nucleic Acids Res., 33, e1.
12. Besaratinia,A. and Pfeifer,G.P. (2005) DNA damage and mutagenesis induced by polycyclic aromatic hydrocarbons. In Luch,A. (ed.), The Carcinogenic Effects of Polycyclic Aromatic Hydrocarbons. Imperial College Press, London, UK, pp. 171-210.
13. Olivier,M., Hussain,S.P., Caron de Fromentel,C., Hainaut,P. and Harris,C.C. (2004) TP53 mutation spectra and load: A tool for generating hypotheses on the etiology of cancer. IARC Sci. Publ., 247-270.
14. Freese,E.B.(1961) Transitions and transversions induced by depurinating agents. Proc. Natl Acad. Sci. USA, 47, 540-545.
15. Freese,E., Bautz,E. and Freese,E.B. (1961) The chemical and mutagenic specificity of hydroxylamine. Proc. Natl Acad. Sci. USA, 47, 845-855.
16. Nomura,M. and Benzer,S. (1961) The nature of the 'deletion' mutants in the rII region of phage T4. J. Mol. Biol., 3, 684-692.
17. Chu,E.H. and Malling,H.V. (1968) Mammalian cell genetics. II. Chemical induction of specific locus mutations in Chinese hamster cells in vitro. Proc. Natl Acad. Sci. USA, 61, 1306-1312.
18. Thilly,W.G. (1990) Mutational spectrometry in animal toxicity testing. Annu. Rev. Pharmacol. Toxicol., 30, 369-385.
19. Skandalis,A. and Glickman,B.W. (1990) Endogenous gene systems for the study of mutational specificity in mammalian cells. Cancer Cells, 2, 79-83.
20. Hussain,S.P. and Harris,C.C. (1998) Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes. Cancer Res., 58, 4023-4037.
21. Thilly,W.G. (2003) Have environmental mutagens caused oncomutations in people? Nat. Genet., 34, 255-259.
22. Daya-Grosjean,L. and Sarasin,A. (2005) The role of UV induced lesions in skin carcinogenesis: An overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat. Res., 571, 43-56.
23. Melnikova,V.O. and Ananthaswamy,H.N. (2005) Cellular and molecular events leading to the development of skin cancer. Mutat. Res., 571, 91-106.
24. Pfeifer,G.P., You,Y.H. and Besaratinia,A. (2005) Mutations induced by ultraviolet light. Mutat. Res., 571, 19-31.
25. Wogan,G.N. (1999) Aflatoxin as a human carcinogen. Hepatology, 30, 573-575.
26. Yu,M.C. and Yuan,J.M. (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology, 127, S72-S78.
27. Groopman,J.D. and Kensler,T.W. (2005) Role of metabolism and viruses in aflatoxin-induced liver cancer. Toxicol. Appl. Pharmacol., 206, 131-137.
28. Mumford,J.L., He,X.Z., Chapman,R.S. et al. (1987) Lung cancer and indoor air pollution in Xuan Wei, China. Science, 235, 217-220.
29. DeMarini,D.M., Landi,S., Tian,D. et al. (2001) Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions. Cancer Res., 61, 6679-6681.
30. Denissenko,M.F., Pao,A., Tang,M. and Pfeifer,G.P. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science, 274, 430-432.
31. Smith,L.E., Denissenko,M.F., Bennett,W.P., Li,H., Amin,S., Tang,M. and Pfeifer,G.P. (2000) Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J. Natl Cancer Inst., 92, 803-811.
32. Feng,Z., Hu,W., Chen,J.X., Pao,A., Li,H., Rom,W., Hung,M.C. and Tang,M.S. (2002) Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J. Natl Cancer Inst., 94, 1527-1536.
33. Hill,A.B. (1965) The environment and disease: Association or causation? Proc. R. Soc. Med., 58, 295-300.
34. Rundle,A.G., Vineis,P. and Ahsan,H. (2005) Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol. Biomarkers Prev., 14, 1899-1907.
35. Tang,D., Phillips,D.H., Stampfer,M. et al. (2001) Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res., 61, 6708-6712.
36. Singer,B. and Essigmann,J.M. (1991) Site-specific mutagenesis: retrospective and prospective. Carcinogenesis, 12, 949-955.
37. Loechler,E.L. (1996) The role of adduct site-specific mutagenesis in understanding how carcinogen-DNA adducts cause mutations: Perspective, prospects and problems. Carcinogenesis, 17, 895-902.
38. Heddle,J.A., Dean,S., Nohmi,T. et al. (2000) In vivo transgenic mutation assays. Environ. Mol. Mutagen., 35, 253-259.
39. Lambert,I.B., Singer,T.M., Boucher,S.E. and Douglas,G.R. (2005) Detailed review of transgenic rodent mutation assays. Mutat. Res., 590, 1-280.
40. Pfeifer,G.P., Chen,H.H., Komura,J. and Riggs,A.D. (1999) Chromatin structure analysis by ligation-mediated and terminal transferase-mediated polymerase chain reaction. Methods Enzymol., 304, 548-571.
41. Maxam,A.M. and Gilbert,W. (1977) A new method for sequencing DNA. Proc. Natl Acad. Sci. USA, 74, 560-564.
42. Pfeifer,G.P., Drouin,R., Riggs,A.D. and Holmquist,G.P. (1991) In vivo mapping of a DNA adduct at nucleotide resolution: Detection of pyrimidine (6-4) pyrimidone photoproducts by ligation-mediated polymerase chain reaction. Proc. Natl Acad. Sci. USA, 88, 1374-1378.
43. Pfeifer,G.P., Drouin,R., Riggs,A.D. and Holmquist,G.P. (1992) Binding of transcription factors creates hot spots for UV photoproducts in vivo. Mol. Cell. Biol., 12, 1798-1804.
44. O'Connor,T.R. and Laval,J. (1989) Physical association of the 2,6-diamino-4-hydroxy-5N-formamidopyrimidine-DNA glycosylase of Escherichia coli and an activity nicking DNA at apurinic/apyrimidinic sites. Proc. Natl Acad. Sci. USA, 86, 5222-5226.
45. Selby,C.P. and Sancar,A. (1990) Structure and function of the (A)BC excinuclease of Escherichia coli. Mutat. Res., 236, 203-211.
46. Pfeifer,G.P. (2005) Measuring the formation and repair of DNA damage by ligation-mediated PCR. In Henderson,D.S. (ed.), DNA Repair Protocols Mammalian Systems. Humana Press, Totowa, NJ, pp. 201-212.
47. Komura,J. and Riggs,A.D. (1998) Terminal transferase-dependent PCR: A versatile and sensitive method for in vivo footprinting and detection of DNA adducts. Nucleic Acids Res., 26, 1807-1811.
48. Schmidt,W.M. and Mueller,M.W. (1996) Controlled ribonucleotide tailing of cDNA ends (CRTC) by terminal deoxynucleotidyl transferase: A new approach in PCR-mediated analysis of mRNA sequences. Nucleic Acids Res., 24, 1789-1791.
49. McKinzie,P.B., Delongchamp,R.R., Heflich,R.H. and Parsons,B.L. (2001) Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. Mutat. Res., 489, 47-78.
50. Winton,D.J., Blount,M.A. and Ponder,B.A. (1988) A clonal marker induced by mutation in mouse intestinal epithelium. Nature, 333, 463-466.
51. Sills,R.C., Boorman,G.A., Neal,J.E., Hong,H.L. and Devereux,T.R. (1999) Mutations in ras genes in experimental tumours of rodents. IARC Sci. Publ., 55-86.
52. Malumbres,M. and Barbacid,M. (2003) RAS oncogenes: The first 30 years. Nat. Rev. Cancer, 3, 459-465.
53. Robles,A.I., Linke,S.P. and Harris,C.C. (2002) The p53 network in lung carcinogenesis. Oncogene, 21, 6898-6907.
54. Hofseth,L.J., Hussain,S.P. and Harris,C.C. (2004) p53: 25 years after its discovery. Trends Pharmacol. Sci., 25, 177-181.
55. Hainaut,P. and Pfeifer,G.P. (2001) Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis, 22, 367-374.
56. Hussain,S.P., Amstad,P., Raja,K. et al. (2001) Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res., 61, 6350-6355.
57. Albertini,R.J. (2001) HPRT mutations in humans: Biomarkers for mechanistic studies. Mutat. Res., 489, 1-16.
58. Seegmiller,J.E. Rosenbloom,F.M. and Kelley,W.N. (1967) Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science, 155, 1682-1684.
59. Khalili,H., Zhang,F.J., Harvey,R.G. and Dipple,A. (2000) Mutagenicity of benzo[a]pyrene-deoxyadenosine adducts in a sequence context derived from the p53 gene. Mutat. Res., 465, 39-44.
60. Thybaud,V., Dean,S., Nohmi,T. et al. (2003) In vivo transgenic mutation assays. Mutat. Res., 540, 141-151.
61. Mellon,I., Spivak,G. and Hanawalt,P.C. (1987) Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene. Cell, 51, 241-249.
62. Tao,K.S., Urlando,C. and Heddle,J.A. (1993) Comparison of somatic mutation in a transgenic versus host locus. Proc. Natl Acad. Sci. USA, 90, 10681-10685.
63. Shane,B.S., de Boer,J., Watson,D.E., Haseman,J.K., Glickman,B.W. and Tindall,K.R. (2000) LacI mutation spectra following benzo[a]pyrene treatment of Big Blue mice. Carcinogenesis, 21, 715-725.
64. Yoon,J.H., Smith,L.E., Feng,Z., Tang,M., Lee,C.S. and Pfeifer,G.P. (2001) Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: Similarities with the p53 mutation spectrum in smoking-associated lung cancers. Cancer Res., 61, 7110-7117.
65. You,Y.H. and Pfeifer,G.P. (2001) Similarities in sunlight-induced mutational spectra of CpG-methylated transgenes and the p53 gene in skin cancer point to an important role of 5-methylcytosine residues in solar UV mutagenesis. J. Mol. Biol., 305, 389-399.
66. Skopek,T.R., Kort,K.L., Marino,D.R., Mittal,L.V., Umbenhauer,D.R., Laws,G.M. and Adams,S.P. (1996) Mutagenic response of the endogenous hprt gene and lacI transgene in benzo[a]pyrene-treated Big Blue B6C3F1 mice. Environ. Mol. Mutagen., 28, 376-384.
67. Mittelstaedt,R.A., Manjanatha,M.G., Shelton,S.D., Lyn-Cook,L.E., Chen,J.B., Aidoo,A., Casciano,D.A. and Heflich,R.H. (1998) Comparison of the types of mutations induced by 7,12-dimethylbenz[a]anthracene in the lacI and hprt genes of Big Blue rats. Environ. Mol. Mutagen., 31, 149-156.
68. Dean,S.W., Brooks,T.M., Burlinson,B., Mirsalis,J., Myhr,B., Recio,L. and Thybaud,V. (1999) Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens. Mutagenesis, 14, 141-151.
69. Lijinsky,W. (1993) Species differences in carcinogenesis. In Vivo, 7, 65-72.
70. Kohler,S.W., Provost,G.S., Kretz,P.L., Dycaico,M.J., Sorge,J.A. and Short,J.M. (1990) Development of a short-term, in vivo mutagenesis assay: The effects of methylation on the recovery of a lambda phage shuttle vector from transgenic mice. Nucleic Acids Res., 18, 3007-3013.
71. Jakubczak,J.L., Merlino,G., French,J.E., Muller,W.J., Paul,B., Adhya,S. and Garges,S. (1996) Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target. Proc. Natl Acad. Sci. USA, 93, 9073-9078.
72. Swiger,R.R., Cosentino,L., Shima,N., Bielas,J.H., Cruz-Munoz,W. and Heddle,J.A. (1999) The cII locus in the MutaMouse system. Environ. Mol. Mutagen., 34, 201-207.
73. Zhang,X.B., Felton,J.S., Tucker,J.D., Urlando,C. and Heddle,J.A. (1996) Intestinal mutagenicity of two carcinogenic food mutagens in transgenic mice: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and amino(alpha)carboline. Carcinogenesis, 17, 2259-2265.
74. Dycaico,M.J., Stuart,G.R., Tobal,G.M., de Boer,J.G., Glickman,B.W. and Provost,G.S. (1996) Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/lacI transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis, 17, 2347-2356.
75. Besaratinia,A. and Pfeifer,G.P. (2003) Enhancement of the mutagenicity of benzo(a)pyrene diol epoxide by a nonmutagenic dose of ultraviolet A radiation. Cancer Res., 63, 8708-8716.
76. Bol,S.A., Horlbeck,J., Markovic,J., de Boer,J.G., Turesky,R.J. and Constable,A. (2000) Mutational analysis of the liver, colon and kidney of Big Blue rats treated with 2-amino-3-methylimidazo[4,5-f]quinoline. Carcinogenesis, 21, 1-6.
77. Besaratinia,A. and Pfeifer,G.P. (2004) Biological consequences of 8-methoxypsoralen-photoinduced lesions: Sequence-specificity of mutations and preponderance of T to C and T to A mutations. J. Invest. Dermatol., 123, 1140-1146.
78. Chen,T., Mittelstaedt,R.A., Beland,F.A., Heflich,R.H., Moore,M.M. and Parsons,B.L. (2005) 4-Aminobiphenyl induces liver DNA adducts in both neonatal and adult mice but induces liver mutations only in neonatal mice. Int. J. Cancer, 117, 182-187.
79. Besaratinia,A., Synold,T.W., Xi,B. and Pfeifer,G.P. (2004) G-to-T transversions and small tandem base deletions are the hallmark of mutations induced by ultraviolet A radiation in mammalian cells. Biochemistry, 43, 8169-8177.
80. Shane,B.S., Smith-Dunn,D.L., de Boer,J.G., Glickman,B.W. and Cunningham,M.L. (2000) Mutant frequencies and mutation spectra of dimethylnitrosamine (DMN) at the lacI and cII loci in the livers of Big Blue transgenic mice. Mutat. Res., 452, 197-210.
81. Besaratinia,A. and Pfeifer,G.P. (2004) Genotoxicity of acrylamide and glycidamide. J. Natl Cancer Inst., 96, 1023-1029.
82. Mirsalis,J.C., Shimon,J.A., Johnson,A., Fairchild,D., Kanazawa,N., Nguyen,T., de Boer,J., Glickman,B. and Winegar,R.A. (2005) Evaluation of mutant frequencies of chemically induced tumors and normal tissues in lambda/cII transgenic mice. Environ. Mol. Mutagen., 45, 17-35.
83. Besaratinia,A. and Pfeifer,G.P. (2005) Investigating DNA adduct-targeted mutagenicity of tamoxifen: Preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells. Biochemistry, 44, 8418-8427.
84. Tornaletti,S. and Pfeifer,G.P. (1995) Complete and tissue-independent methylation of CpG sites in the p53 gene: Implications for mutations in human cancers. Oncogene, 10, 1493-1499.
85. Denissenko,M.F., Pao,A., Pfeifer,G.P. and Tang,M. (1998) Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene, 16, 1241-1247.
86. Denissenko,M.F., Chen,J.X., Tang,M.S. and Pfeifer,G.P. (1997) Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc. Natl Acad. Sci. USA, 94, 3893-3898.
87. Chen,J.X., Zheng,Y., West,M. and Tang,M.S. (1998) Carcinogens preferentially bind at methylated CpG in the p53 mutational hot spots. Cancer Res., 58, 2070-2075.
88. Loeb,L.A., Loeb,K.R. and Anderson,J.P. (2003) Multiple mutations and cancer. Proc. Natl Acad. Sci. USA, 100, 776-781.
89. Wistuba, I.I., Gazdar,A.F. and Minna,J.D. (2001) Molecular genetics of small cell lung carcinoma. Semin. Oncol., 28, 3-13.
90. Denissenko,M.F., Koudriakova,T.B., Smith,L., O'Connor,T.R., Riggs,A.D. and Pfeifer,G.P. (1998) The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene, 17, 3007-3014.
91. Ross,R.K., Yuan,J.M., Yu,M.C., Wogan,G.N., Qian,G.S., Tu,J.T., Groopman,J.D., Gao,Y.T. and Henderson,B.E. (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339, 943-946.
92. Unsal,H., Yakicier,C., Marcais,C., Kew,M., Volkmann,M., Zentgraf H., Isselbacher,K.J. and Ozturk,M. (1994) Genetic heterogeneity of hepatocellular carcinoma. Proc. Natl Acad. Sci. USA, 91, 822-826.
93. Hursting,S.D., Nunez,N.P., Patel,A.C., Perkins,S.N., Lubet,R.A. and Barrett,J.C. (2005) The utility of genetically altered mouse models for nutrition and cancer chemoprevention research. Mutat. Res., 576, 80-92.
94. Greenblatt,M.S., Bennett,W.P., Hollstein,M. and Harris,C.C. (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
95. Hollstein,M., Sidransky,D., Vogelstein,B. and Harris,C.C. (1991) p53 mutations in human cancers. Science, 253, 49-53.
96. Rideout,W.M. III, Coetzee,G.A., Olumi,A.F. and Jones,P.A. (1990) 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science, 249, 1288-1290.
97. Ambs,S., Bennett,W.P., Merriam,W.G., Ogunfusika,M.O., Oser,S.M., Harrington,A.M., Shields,P.G., Felley-Bosco,E., Hussain,S.P. and Harris,C.C. (1999) Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J. Natl Cancer Inst., 91, 86-88.